Literature DB >> 19218269

DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome.

Aude-Marie Lepagnol-Bestel1, Agnes Zvara, Gilles Maussion, Frédérique Quignon, Bedel Ngimbous, Nicolas Ramoz, Sandrine Imbeaud, Yann Loe-Mie, Karim Benihoud, Nicolas Agier, Paul A Salin, Ana Cardona, Suonavy Khung-Savatovsky, Pekka Kallunki, Jean-Maurice Delabar, Laszlo G Puskas, Hervé Delacroix, Lawrence Aggerbeck, Anne-Lise Delezoide, Olivier Delattre, Philip Gorwood, Jean-Marie Moalic, Michel Simonneau.   

Abstract

The molecular mechanisms that lead to the cognitive defects characteristic of Down syndrome (DS), the most frequent cause of mental retardation, have remained elusive. Here we use a transgenic DS mouse model (152F7 line) to show that DYRK1A gene dosage imbalance deregulates chromosomal clusters of genes located near neuron-restrictive silencer factor (REST/NRSF) binding sites. We found that Dyrk1a binds the SWI/SNF complex known to interact with REST/NRSF. The mutation of a REST/NRSF binding site in the promoter of the REST/NRSF target gene L1cam modifies the transcriptional effect of Dyrk1a-dosage imbalance on L1cam. Dyrk1a dosage imbalance perturbs Rest/Nrsf levels with decreased Rest/Nrsf expression in embryonic neurons and increased expression in adult neurons. Using transcriptome analysis of embryonic brain subregions of transgenic 152F7 mouse line, we identified a coordinated deregulation of multiple genes that are responsible for dendritic growth impairment present in DS. Similarly, Dyrk1a overexpression in primary mouse cortical neurons induced severe reduction of the dendritic growth and dendritic complexity. We propose that DYRK1A overexpression-related neuronal gene deregulation via disturbance of REST/NRSF levels, and the REST/NRSF-SWI/SNF chromatin remodelling complex, significantly contributes to the neural phenotypic changes that characterize DS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19218269     DOI: 10.1093/hmg/ddp047

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  57 in total

Review 1.  Trisomy 21 and early brain development.

Authors:  Tarik F Haydar; Roger H Reeves
Journal:  Trends Neurosci       Date:  2011-12-09       Impact factor: 13.837

2.  Eradicating the mediators of neuronal death with a fine-tooth comb.

Authors:  R Suzanne Zukin
Journal:  Sci Signal       Date:  2010-06-08       Impact factor: 8.192

Review 3.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

Review 4.  REST and CoREST are transcriptional and epigenetic regulators of seminal neural fate decisions.

Authors:  Irfan A Qureshi; Solen Gokhan; Mark F Mehler
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

5.  Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a.

Authors:  Aurore Thomazeau; Olivier Lassalle; Jillian Iafrati; Benoit Souchet; Fayçal Guedj; Nathalie Janel; Pascale Chavis; Jean Delabar; Olivier J Manzoni
Journal:  J Neurosci       Date:  2014-01-22       Impact factor: 6.167

6.  Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.

Authors:  Karol Dowjat; Tatyana Adayev; Wojciech Kaczmarski; Jerzy Wegiel; Yu-Wen Hwang
Journal:  J Neuropathol Exp Neurol       Date:  2012-12       Impact factor: 3.685

7.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

Review 8.  Histone regulation in the CNS: basic principles of epigenetic plasticity.

Authors:  Ian Maze; Kyung-Min Noh; C David Allis
Journal:  Neuropsychopharmacology       Date:  2012-07-25       Impact factor: 7.853

9.  A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions.

Authors:  Tao Yu; Zhongyou Li; Zhengping Jia; Steven J Clapcote; Chunhong Liu; Shaomin Li; Suhail Asrar; Annie Pao; Rongqing Chen; Ni Fan; Sandra Carattini-Rivera; Allison R Bechard; Shoshana Spring; R Mark Henkelman; George Stoica; Sei-Ichi Matsui; Norma J Nowak; John C Roder; Chu Chen; Allan Bradley; Y Eugene Yu
Journal:  Hum Mol Genet       Date:  2010-05-04       Impact factor: 6.150

10.  Diagnosing and Treating Nervous System Disorders by Targeting Novel Classes of Non-coding RNAs.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Int Drug Discov       Date:  2011 Jun-Jul
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.